Log in to search using one of your social media accounts:

 

SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in HNC
(InSilico Medicine, Inc.) The researchers identified that SMAD4 loss results in cetuximab resistance in vitro and poor survival in HPV-negative HNSCC patients and in vivo models. Using OncoFinder (an innovative bioinformatic tool currently rebranded as iPANDA), they revealed a signature of pro-survival and anti-apoptotic pathways specifically dysregulated in SMAD4-low HNSCCs and indicate JNK and MAPK activation as potential mediators of cetuximab resistance. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 7, 2017 Category: International Medicine & Public Health Source Type: news

Three-Weekly Cisplatin Superior to Weekly Dose in Head and Neck Cancer
Three-weekly cisplatin is superior to a weekly dose in preventing locoregional relapse when combined with radiotherapy in head and neck squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - July 3, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Head & Neck Cancer News Source Type: news

Tumor PD-L2 expression may predict patient response to anti-PD-1 immunotherapy
(American Association for Cancer Research) PD-L2 protein expression in human tumors was associated with clinical response to pembrolizumab (Keytruda), an anti-PD-1 immunotherapy, independent of PD-L1 expression, in patients with head and neck squamous cell carcinoma (HNSCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 15, 2017 Category: International Medicine & Public Health Source Type: news

DNA vaccine with immunotherapy may treat HPV cancers
A new vaccine therapy has the potential to generate immune responses in patients with head and neck squamous cell carcinoma in HPV patients. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 31, 2017 Category: Consumer Health News Source Type: news

Immunotherapy with DNA vaccine shows promise for HPV-related head and neck cancer
(University of Pennsylvania School of Medicine) A novel vaccine therapy can generate immune responses in patients with head and neck squamous cell carcinoma (HNSCCa), according to researchers at the Abramson Cancer Center of the University of Pennsylvania. The treatment specifically targets human papillomavirus (HPV), which is frequently associated with HNSCCa, to trigger the immune response. Researchers will present the results of their pilot study during the 2017 American Society of Clinical Oncology Annual Meeting in Chicago (Abstract #6073). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2017 Category: Cancer & Oncology Source Type: news

Head & neck cancer recurrence following radiation associated w high tumor PD-L1 expression
(American Association for Cancer Research) Recurrence of head and neck squamous cell carcinoma (HNSCC) negative for human papillomavirus (HPV) following radiation therapy was associated with high tumor levels of the protein PD-L1. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 5, 2017 Category: Cancer & Oncology Source Type: news

Head & neck cancer recurrence following radiation associated with high tumor PD-L1 expression
(American Association for Cancer Research) Recurrence of head and neck squamous cell carcinoma (HNSCC) negative for human papillomavirus (HPV) following radiation therapy was associated with high tumor levels of the protein PD-L1. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 5, 2017 Category: Cancer & Oncology Source Type: news

HNSCC: Intratumoral Injection of T4 Immunotherapy Bypasses Homing (CME/CE)
(MedPage Today) -- Good safety profile, but no objective CR/PR in dose-escalation Phase I study (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - April 6, 2017 Category: Journals (General) Source Type: news

PD-1 Inhibitor Active in Refractory HNSCC (CME/CE)
(MedPage Today) -- Overall response rate of 16% with pembrolizumab (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 25, 2017 Category: Hematology Source Type: news

Targeting cancer stem cells improves treatment effectiveness, prevents metastasis
Targeting cancer stem cells may be a more effective way to overcome cancer resistance and prevent the spread of squamous cell carcinoma — the most common head and neck cancer and the second-most common skin cancer, according to a new study. Head and neck squamous cell carcinoma is a highly invasive form of cancer and frequently spreads to the cervical lymph nodes. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 10, 2017 Category: Science Source Type: news

Targeting cancer stem cells improves treatment effectiveness and prevents metastasis
This study shows that for the first time, targeting the proliferating tumor mass and dormant cancer stem cells with combination therapy effectively inhibited tumor growth and prevented metastasis compared to monotherapy in mice,” said Wang, who is a member of the UCLA Jonsson Comprehensive Canc er Center and of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. “Our discovery could be applied to other solid tumors such as breast and colon cancer, which also frequently metastasizes to lymph nodes or distant organs.”“With this new and exciting study, Dr. Wang and ...
Source: UCLA Newsroom: Health Sciences - March 9, 2017 Category: Universities & Medical Training Source Type: news

Roadmap to more personalized cancer treatment
People with advanced head and neck squamous cell carcinoma and the KRAS-variant inherited genetic mutation have significantly improved survival when given a short course of the drug cetuximab in combination with standard chemotherapy and radiation, research has found. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 22, 2016 Category: Science Source Type: news

Study provides roadmap to more personalized cancer treatment
Milo Mitchell/UCLA Jonsson Comprehensive Cancer CenterUCLA ’s Dr. Joanne Weidhaas explains her latest research, which could lead to more personalized treatments for head and neck cancer. FINDINGSResearchers have found that people with advanced head and neck squamous cell carcinoma and the KRAS-variant inherited genetic mutation have significantly improved survival when given a short course of the drug cetuximab in combination with standard chemotherapy and radiation.The study was led by UCLA Jonsson Comprehensive Cancer Center member Dr. Joanne Weidhaas in collaboration with colleagues at the NRG Oncology RTOG. ...
Source: UCLA Newsroom: Health Sciences - December 22, 2016 Category: Universities & Medical Training Source Type: news

I get by with help from my friends: Maintaining immune cells in head and neck cancer
(Medical University of South Carolina) In an article published Sept. 22, 2016 in Frontiers in Immunology, researchers at the Medical University of South Carolina and the Ralph H. Johnson VA Medical Center report that inhibiting prostaglandin production slows the progression of premalignant lesions to head and neck squamous cell carcinoma. Preclinical studies showed that treatment of premalignant lesions with indomethacin, a nonsteroidal anti-inflammatory drug similar to aspirin, increased the presence of immune cells and lessened tumor burden. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 30, 2016 Category: Global & Universal Source Type: news

FDA lifts clinical hold on AstraZeneca cancer drug studies
The Food and Drug Administration has lifted a partial clinical hold it placed last month on the enrollment of new patients in a late-stage studies AstraZeneca was conducting on new treatments for head and neck cancer. The clinical trials were for durvalumab as a monotherapy and in combination with tremelimumab, an experimental immuno-oncology drug also in AstraZeneca’s pipeline, for treating head and neck squamous cell carcinoma. The FDA placed a partial clinical hold on the trials in late October… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 22, 2016 Category: Pharmaceuticals Authors: John George Source Type: news

IMRT associated with reduction in patient reported xerostomia
(NRG Oncology) A pooled analysis of data from NRG Oncology studies RTOG 0129 and 0522 compared intensity-modulated radiotherapy (IMRT) with three-dimensional conformal radiotherapy for patients treated for locally advanced head and neck squamous cell carcinoma. The study found that IMRT was associated with significantly reduced xerostomia and feeding tube dependency after treatment, especially in oropharyngeal cancer patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 3, 2016 Category: Cancer & Oncology Source Type: news

FDA Approves Keytruda (Pembrolizumab) for Head and Neck Cancer
By Stacy SimonThe US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) to treat people with head and neck squamous cell carcinoma that has spread or come back after previous chemotherapy treatment. It’s the first immunotherapy drug approved for head and neck cancer. Keytruda is already approved for melanoma and non-small cell lung cancer.The FDA based its approval on a clinical trial of 174 people with head and neck squamous cell carcinoma that had spread or come back after they were treated with platinum-based chemotherapy. Tumors shrank or disappeared in 16% of the participants who were given...
Source: American Cancer Society :: News and Features - August 9, 2016 Category: Cancer & Oncology Tags: Oral Cavity and Oropharyngeal Cancer Source Type: news

FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA®(pembrolizumab), the company ’s anti-PD-1 (programmed death receptor-1) therapy, at a fixed dose of 200 mg every three weeks, for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherap y.Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orA...
Source: Merck.com - Product News - August 8, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

FDA Approves Merck ’s Keytruda (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
KENILWORTH, N.J.--(BUSINESS WIRE)--August 5, 2016 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab), the company ’s anti-PD-1... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 5, 2016 Category: Drugs & Pharmacology Source Type: news

Updated Findings from KEYNOTE-012 for KEYTRUDA® (pembrolizumab) Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Previously Treated Recurrent or Metastatic Head and Neck Cancer
Dateline City: KENILWORTH, N.J. Response Rates from KEYNOTE-055 Show Nearly One in Five Patients Responding with KEYTRUDA; Results Confirm Findings from KEYNOTE-012 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data with KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, as a monotherapy from two studies (KEYNOTE-012 and KEYNOTE-055) in heavily pre-treated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). ...
Source: Merck.com - Research and Development News - June 6, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO cancer Keytruda MSD Source Type: news

Updated Findings from KEYNOTE-012 for KEYTRUDA ® (pembrolizumab) Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Previously Treated Recurrent or Metastatic Head and Neck Cancer
Dateline City: KENILWORTH, N.J. Response Rates from KEYNOTE-055 Show Nearly One in Five Patients Responding with KEYTRUDA; Results Confirm Findings from KEYNOTE-012 KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data with KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, as a monotherapy from two studies (KEYNOTE-012 and KEYNOTE-055) in heavily pre-treated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Data are being presented at the 52 nd An...
Source: Merck.com - Research and Development News - June 6, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO cancer Keytruda MSD Source Type: news

Sentinel node biopsies may be useful in head and neck squamous cell carcinoma
ORLANDO – Sentinel node biopsies may be a useful staging tool for patients with cutaneous squamous cell carcinomas of the head and neck. These patients – especially those with compromised immune systems – appear to be at sufficiently high risk of metastasis to justify the procedure, Dr. Jonathan... (Source: Skin and Allergy News)
Source: Skin and Allergy News - May 23, 2016 Category: Dermatology Source Type: news

Oral Hygiene Habits and Survival of HNSCC PatientsOral Hygiene Habits and Survival of HNSCC Patients
Can preventive dental care and good oral hygiene improve survival of patients with head and neck squamous cell carcinoma? BMC Oral Health (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 19, 2016 Category: Consumer Health News Tags: Dental & Oral Health Journal Article Source Type: news

Hope for Advanced HNSCC at Last From ImmunotherapyHope for Advanced HNSCC at Last From Immunotherapy
Nivolumab significantly improved survival for patients with advanced refractory head and neck cancer. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 19, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Recurrent or Metastatic Head and Neck Cancer, and Grants Priority Review
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. Language: English ...
Source: Merck.com - Product News - April 13, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer FDA Head and Neck Cancer Keytruda NYSE:MRK Source Type: news

FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA ® (pembrolizumab) in Recurrent or Metastatic Head and Neck Cancer, and Grants Priority Review
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. Language: English Contact: Merck Medi...
Source: Merck.com - Product News - April 13, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer FDA Head and Neck Cancer Keytruda NYSE:MRK Source Type: news

Non-HPV-16 genotypes linked to poor HNSCC survival
medwireNews: Patients with head and neck squamous cell carcinoma (HNSCC) who harbour human papillomavirus (HPV) genotypes other than HPV-16 have significantly worse overall survival (OS) than those te ... (Source: MedWire News)
Source: MedWire News - March 31, 2016 Category: Consumer Health News Tags: Head and neck cancer Source Type: news

Chemoradiation May Increase Survival for a Subset of Elderly Head and Neck Cancer Patients (University of Colorado Cancer Center)
The addition of chemotherapy (CT) to radiation therapy (RT) improves survival rates among a subset of elderly head and neck cancer patients, specifically those ages 71 to 79 with low comorbidity scores and advanced disease stage, according to University of Colorado Cancer Center research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium. While previous research has demonstrated the efficacy of combining CT with RT to improve survival for HNSCC patients, this improvement had ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - February 20, 2016 Category: Cancer & Oncology Source Type: news

HPV16 in the Mouth Linked to Increased Risk for HNSCCHPV16 in the Mouth Linked to Increased Risk for HNSCC
The detection of human papillomavirus (HPV) type 16 in the mouth was associated with a 22-fold increased risk for oropharyngeal cancer in a new study. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 22, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Spit-and-Stick Test Could Be Biomarker for HNSCCSpit-and-Stick Test Could Be Biomarker for HNSCC
A much-needed biomarker for head and neck squamous cell carcinoma (HNSCC) that assesses tumor DNA shed in plasma and saliva is in the works. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 1, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors
Adoptive cell therapy using gene-modified T-cells has achieved impressive results in the treatment of B-cell malignancies. However, the development of similar strategies to treat solid tumors raises challenges with respect to tumor antigen selection and the achievement of efficient T-cell homing, survival and sustained effector function within the tumor microenvironment. To address these challenges, we have developed a gene-modified cellular therapy called T4 immunotherapy. To generate T4 immunotherapy, autologous T-cells are engineered by retroviral transduction to co-express two transgenes: (1) a chimeric antigen recepto...
Source: Springer protocols feed by Cancer Research - June 26, 2015 Category: Cancer & Oncology Source Type: news

Erythropoietin combined with radiation therapy does not improve local-regional control in anemic patients with head and neck cancer
Long-term analysis of Radiation Therapy Oncology Group 9903 demonstrates that the addition of erythropoietin did not improve local-regional control for anemic patients with head and neck squamous cell carcinoma who receive radiation therapy or chemoradiation, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 6, 2015 Category: Science Source Type: news

Erythropoietin combined with radiation therapy does not improve local-regional control in anemic patients with head and neck cancer
(American Society for Radiation Oncology) Long-term analysis of Radiation Therapy Oncology Group 9903 demonstrates that the addition of erythropoietin did not improve local-regional control for anemic patients with head and neck squamous cell carcinoma who receive radiation therapy or chemoradiation, according to a study published in the April 1, 2015 issue of the International Journal of Radiation Oncology * Biology * Physics. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 6, 2015 Category: Cancer & Oncology Source Type: news

Potential prognostic marker for recurrence of head and neck squamous cell carcinoma
The first evidence that the mediator complex subunit 15 (MED15) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma (HNSCC) has been discovered by researchers. MED15 overexpression was found to be associated with higher mortality rates in HNSCC patients with cancer recurrence, particularly in oral cavity/oropharyngeal tumors, according to the study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 20, 2015 Category: Science Source Type: news

Researchers ID potential prognostic marker for recurrence of head & neck squamous cell carcinoma
(Elsevier Health Sciences) A new study provides the first evidence that the mediator complex subunit 15 (MED15) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma (HNSCC). MED15 overexpression was found to be associated with higher mortality rates in HNSCC patients with cancer recurrence, particularly in oral cavity/oropharyngeal tumors, according to the study published in The American Journal of Pathology. MED15 overexpression was also associated with heavy alcohol consumption, which is an HNSCC risk factor. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 20, 2015 Category: Global & Universal Source Type: news

Researchers ID potential prognostic marker for recurrence of head and neck squamous cell carcinoma
(Elsevier Health Sciences) A new study provides the first evidence that the mediator complex subunit 15 (MED15) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma (HNSCC). MED15 overexpression was found to be associated with higher mortality rates in HNSCC patients with cancer recurrence, particularly in oral cavity/oropharyngeal tumors, according to the study published in the American Journal of Pathology. MED15 overexpression was also associated with heavy alcohol consumption, which is an HNSCC risk factor. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 20, 2015 Category: Cancer & Oncology Source Type: news

New look at complex head and neck tumor behavior
Head and neck squamous cell cancer (HNSCC) ranks among the top ten most prevalent cancers in the United States. Despite its prevalence, little is known about how this cancer develops and spreads. However, researchers now offer critical new information about head and neck cancers. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 4, 2015 Category: Science Source Type: news

Genetics Home Reference: head and neck squamous cell carcinoma
http://ghr.nlm.nih.gov/condition/head-and-neck-squamous-cell-carcinoma (Source: NLM General Announcements)
Source: NLM General Announcements - January 6, 2015 Category: Databases & Libraries Source Type: news

Mutant-Allele Tumor Heterogeneity (MATH) in head, neck squamous cell carcinoma patients is effective marker, along with HPV status, of improved patient outcome
Evaluating next-generation sequencing (NGS) data and associated clinical records of head and neck squamous cell carcinoma (HNSCC) patients from several institutions, made available through The Cancer Genome Atlas (TCGA), showed that combining Mutant-Allele Tumor Heterogeneity (MATH) as a biomarker with the patient’s HPV status provides an effective indicator of improved patient outcome, according to research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 20, 2014 Category: Science Source Type: news

MATH, HPV status in HNSCC patients effective markers of improved patient outcome
(American Society for Radiation Oncology) Evaluating next-generation sequencing data and associated clinical records of head and neck squamous cell carcinoma patients from several institutions, made available through The Cancer Genome Atlas, showed that combining mutant-allele tumor heterogeneity as a biomarker with the patient's HPV status provides an effective indicator of improved patient outcome, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 20, 2014 Category: Cancer & Oncology Source Type: news

Mechanisms and potential biomarkers identified for tumor cell dormancy
Oncologists have long puzzled over the fact that after cancer treatment, single cancer cells that are dispersed throughout the body - so-called disseminated tumor cells - are quick to grow and form secondary tumors called metastases in certain organs, while in other organs they metastasize more slowly, sometimes decades later. Such is the case with head and neck squamous cell carcinoma (HNSCC) cells, which remain dormant when lodged in bone marrow but rapidly form tumors when they make their way into the lungs. A study published online by Nature Cell Biology by Bragado et al... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 30, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Dental caries show ‘unexpected’ relationship with head and neck cancer
People with dental caries have a reduced risk for developing head and neck squamous cell carcinoma, a large case-control study has found. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - September 25, 2013 Category: Cancer & Oncology Source Type: news

“Dental Cavities May Protect against Oral, Throat Cancers”, CBSNews.com
This article mentions data out of The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute-one of the 23 NCCN Member Institutions.... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - September 12, 2013 Category: Cancer & Oncology Source Type: news

A Promising Drug Can Help Prevent Head And Neck Cancers
Head and neck cancers typically begin in squamous cells that line moist surfaces inside the mouth, nose and throat. Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most common type of cancer in the United States, and it is sometimes preceded by the appearance of changes inside the oral cavity called precancerous lesions. The most common type of change is a white patch known as a leukoplakia. Because it often takes decades for leukoplakias to develop into HNSCC, there is a window of opportunity to recognize and revert precancerous changes, thus preventing this type of cancer... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 11, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Study Documents Head And Neck Cancer Molecular Tumor Subtypes
Head and neck squamous cell carcinoma (HNSCC) is the seventh most common form of cancer in the United States, but other than an association with the human papillomavirus, no validated molecular profile of the disease has been established. By analyzing data from DNA microarrays, a UNC-led team has completed a study that confirms the presence of four molecular classes of the disease and extends previous results by suggesting that there may be an underlying connection between the molecular classes and observed genomic events, some of which affect known cancer genes... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 26, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news